Literature DB >> 10850350

Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.

M R Walter1, R Bordens, T L Nagabhushan, B R Williams, R B Herberman, C A Dinarello, E C Borden, P P Trotta, S Pestka, L M Pfeffer.   

Abstract

Recombinant alfa interferons (IFN-alpha s) are approved worldwide for the treatment of a variety of cancers and diseases of virologic origin. A series of recent advances in the molecular characterization of recombinant IFN-alpha s have allowed the determination of the three-dimensional IFN-alpha 2b structure by high-resolution x-ray crystallography. We review here recent developments in our understanding of the molecular and physicochemical properties of recombinant IFN-alpha, including our current state of knowledge of the IFN-alpha gene family and the multiple species of human leukocyte IFN. Based on the reported three-dimensional structure of IFN-alpha 2b, we propose a molecular model for the IFN-alpha 2b receptor complex and predict models for the naturally occurring subtypes IFN-alpha 1 and IFN-alpha 8, as well as the synthetic, non-naturally occurring consensus IFN. Such models provide molecular insights into the mechanism of action of IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10850350     DOI: 10.1089/cbr.1998.13.143

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

Review 1.  Biobehavioral outcomes following psychological interventions for cancer patients.

Authors:  Barbara L Andersen
Journal:  J Consult Clin Psychol       Date:  2002-06

2.  [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].

Authors:  D Bruch-Gerharz; J Reifenberger
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

3.  Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.

Authors:  Yuxin Wang; Jing Nan; Belinda Willard; Xin Wang; Jinbo Yang; George R Stark
Journal:  EMBO J       Date:  2016-11-16       Impact factor: 11.598

4.  Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.

Authors:  Shin-Ichiro Kawamoto; Kenji Oritani; Hideo Asada; Isao Takahashi; Jun Ishikawa; Hitoshi Yoshida; Masahide Yamada; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 5.  Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils.

Authors:  Ashley A Stegelmeier; Maedeh Darzianiazizi; Kiersten Hanada; Shayan Sharif; Sarah K Wootton; Byram W Bridle; Khalil Karimi
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

6.  Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report.

Authors:  Gurmit Gill; Hammad Bajwa; Peter Strouhal; Harit N Buch
Journal:  J Med Case Rep       Date:  2016-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.